Reata Pharmaceuticals Stock Market Capitalization
| RETADelisted Stock | USD 109.67 3.31 2.93% |
Reata Pharmaceuticals fundamentals help investors to digest information that contributes to Reata Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Reata Stock. The fundamental analysis module provides a way to measure Reata Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Reata Pharmaceuticals stock.
Reata |
Reata Pharmaceuticals Company Market Capitalization Analysis
Reata Pharmaceuticals' Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Reata Pharmaceuticals Market Capitalization | 6.57 B |
Most of Reata Pharmaceuticals' fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reata Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
CompetitionBased on the recorded statements, the market capitalization of Reata Pharmaceuticals is about 6.57 B. This is 49.26% lower than that of the Pharmaceuticals sector and 38.51% higher than that of the Health Care industry. The market capitalization for all United States stocks is 65.49% higher than that of the company.
Reata Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reata Pharmaceuticals' direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reata Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reata Pharmaceuticals by comparing valuation metrics of similar companies.Reata Pharmaceuticals is currently under evaluation in market capitalization category among its peers.
Reata Fundamentals
| Return On Equity | -1.12 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (14.55) % | |||
| Current Valuation | 6.4 B | |||
| Shares Outstanding | 33.59 M | |||
| Shares Owned By Insiders | 4.10 % | |||
| Shares Owned By Institutions | 88.46 % | |||
| Number Of Shares Shorted | 2.6 M | |||
| Price To Earning | (28.13) X | |||
| Price To Book | 285.94 X | |||
| Price To Sales | 414.73 X | |||
| Revenue | 2.22 M | |||
| Gross Profit | (167.63 M) | |||
| EBITDA | (269.02 M) | |||
| Net Income | (311.9 M) | |||
| Cash And Equivalents | 481.47 M | |||
| Cash Per Share | 13.19 X | |||
| Total Debt | 119.46 M | |||
| Debt To Equity | 2.08 % | |||
| Current Ratio | 10.60 X | |||
| Book Value Per Share | 2.31 X | |||
| Cash Flow From Operations | (204.27 M) | |||
| Short Ratio | 2.81 X | |||
| Earnings Per Share | (2.62) X | |||
| Target Price | 172.45 | |||
| Number Of Employees | 321 | |||
| Beta | 1.42 | |||
| Market Capitalization | 6.57 B | |||
| Total Asset | 514.49 M | |||
| Retained Earnings | (1.57 B) | |||
| Working Capital | 338.81 M | |||
| Current Asset | 87.28 M | |||
| Current Liabilities | 59.63 M | |||
| Z Score | 27.78 | |||
| Net Asset | 514.49 M |
About Reata Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Reata Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reata Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reata Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |